Skip to content

L’Oréal Settles First Hair Relaxer Cancer Trial; 12,700 Lawsuits Still Pending

L’Oréal settled with four women during the first hair relaxer cancer trial, but the deal only covers those plaintiffs. More than 12,700 cases are in the separate federal hair relaxer MDL, and the settlement doesn't touch those. The real test is the first bellwether trial, set for September 2027.

Open container of chemical hair relaxer cream with an application brush, gloves, and comb on a salon counter.
Published:

On November 16, 2026, L’Oréal USA settled with four women who alleged they developed cancer from using the company’s hair relaxer products. The settlement came just one week into the first hair relaxer trial to reach a jury.

While the plaintiffs can close the door on the emotionally challenging litigation, the deal resolves nothing for those still waiting for the next stage of the federal case. It sets no price tag for what the more than 12,700 cases filed in the hair relaxer cancer MDL might be worth.

Women who are part of the federal MDL should understand what the L’Oréal settlement means and doesn’t mean for pending claims.

What Happened in the First Hair Relaxer Cancer Trial?

MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson sued L’Oréal and several other manufacturers in Cook County, Illinois state court in 2023 and 2024. They alleged that years of using chemical hair straighteners caused their gynecologic cancers, including uterine cancer.

Jury selection began November 9, and on November 16, with the trial underway, the parties reached a confidential settlement; there wasn’t a jury verdict.

The case highlighted what many women who used hair relaxers and later developed cancer experienced: they trusted beauty manufacturers to create and sell safe products, and in the end, they paid in the form of serious health effects.

L’Oréal maintains its products are safe, follow regulations and are scientifically evaluated. The value of the hair relaxer settlement in the first case to go to trial is undisclosed, and it doesn’t include an admission of fault.

What Does the Hair Relaxer Settlement Mean for the Federal MDL?

Women who have filed lawsuits in the chemical hair straightener MDL are now wondering if their cases will settle, too. But this outcome doesn’t necessarily mean the 12,700+ plaintiffs in federal court are more likely to settle.

The key difference is that the first hair relaxer trial was filed in Illinois state court, and the settlement only applies to the four plaintiffs. It creates no formula, benchmark payout range or obligation for L’Oréal to resolve anyone else’s claim on similar terms.

But why would a company settle instead of letting a jury decide? One reason is that a verdict is public and permanent; it becomes a data point attorneys can point to in other hair relaxer cancer cases. A confidential settlement avoids that risk while leaving the legal and scientific questions unresolved. That’s a strategic move, not a sign the broader litigation is close to a global resolution.

State Court vs. Federal MDL: What’s the Difference, and Why Does It Matter?

What happens next for thousands of plaintiffs depends on a key distinction: state court and the federal MDL are separate.

The four settled cases were independent lawsuits filed in the same Illinois state courthouse. A settlement or verdict in state court only applies to the individual plaintiffs involved.

Meanwhile, more than 12,700 cases are part of the chemical hair relaxer MDL No. 3060. Lawsuits were consolidated in 2023. But an MDL isn’t a class action; it doesn’t merge cases into one lawsuit or produce one shared payout.

MDLs centralize pretrial work (shared discovery, expert rulings) so that evidence doesn’t have to be presented and litigated 12,700 times.

Instead, a handful of “bellwether” cases that represent plaintiffs and their illnesses are selected to go to trial as a test of how juries and courts might view the evidence.

For thousands of women, the real milestone to watch isn’t this settlement. It’s the first federal bellwether trial, scheduled for September 7, 2027.

But there are notable takeaways from recent court proceedings. Just days before the Cook County settlement, the federal judge declined to exclude testimony from the plaintiffs’ causation expert, letting that fight continue toward 2027. Causation experts use scientific and medical evidence to explain how a product may cause an illness and, in some cases, how it may have contributed to a particular person's diagnosis. Those rulings don’t decide who’s right about the science; manufacturers can still challenge the experts at trial.

What’s Driving Hair Relaxer Lawsuits?

The hair relaxer litigation traces back to an October 2022 study published in the Journal of the National Cancer Institute, which connected hair relaxers to cancer risks.

Researchers followed nearly 34,000 women for close to 11 years and found that those who used hair straighteners more than four times a year were more than twice as likely to develop uterine cancer.

About 60% of frequent users in the study identified as Black women. This detail has been central to claims that hair relaxers were marketed specifically to Black women for decades without adequate safety warnings.

As we previously covered, there are numerous reproductive health concerns associated with hair relaxer use, and other studies have added further evidence to claims.

State Attorneys General File Hair Relaxer Lawsuits

These lawsuits encompass thousands of plaintiffs who developed cancer allegedly caused by chemical straighteners, but now, state attorneys general are taking action.

In September 2026, Arizona became the first state to sue L’Oréal, with Attorney General Kris Mayes accusing the company of concealing cancer risks under the state’s consumer fraud law. Minnesota filed a similar suit in October.

These cases seek penalties, damages and court orders requiring warning labels. They won’t result in individual compensation for injured consumers. But a state court finding that L’Oréal misled women could become persuasive evidence in personal injury litigation.

It’s a reminder that federal regulation hasn’t closed the gap: the FDA has missed deadlines to act on toxic ingredients in hair relaxers.

What to Take Away from the First Hair Relaxer Trial and Settlement

Don’t read this settlement as a signal about timing or value for your own case. The amount is sealed, the terms are specific to four plaintiffs, and the federal MDL’s trajectory hasn’t changed.

If you used chemical hair relaxers regularly and were later diagnosed with uterine, ovarian or another gynecologic cancer, the relevant facts are your exposure history and diagnosis.

For the practical basics on eligibility and the filing process, learn what to know about filing a hair relaxer cancer lawsuit. Also, stay tuned for further MDL progress, expert rulings, bellwether trials, and other state attorneys general following Arizona and Minnesota’s lead.

Legal Examiner Staffer

Legal Examiner Staffer

Legal Examiner staff writers come from diverse journalism and communications backgrounds. They contribute news and insights to inform readers on legal issues, public safety, consumer protection, and other national topics.

All articles
Tags: Legal Health

More in Legal

See all

More from Legal Examiner Staffer

See all

Legal Marketing